About this document
Table 4 Trials RASi by jaromo37 is a document available to read on EtoBox.
The document presents data from various clinical trials of novel KRASG12C inhibitors in metastatic colorectal cancer (mCRC), detailing their efficacy. Key findings include overall response rates (ORR) ranging from 40% to 88.9% and disease control rates (DCR) between 87% and 92.9%. Additionally, median progression-free survival (mPFS) is reported for some trials, indicating the potential effectiveness of these treatments.
- Author
- jaromo37
- Language
- EN